Search

Your search keyword '"Nastouli, E"' showing total 215 results

Search Constraints

Start Over You searched for: Author "Nastouli, E" Remove constraint Author: "Nastouli, E"
215 results on '"Nastouli, E"'

Search Results

3. Lateral flow test engineering and lessons learned from COVID-19

4. Effectiveness of rapid SARS-CoV-2 genome sequencing in supporting infection control for hospital-onset COVID-19 infection: multicenter, prospective study

5. Paediatric European Network for Treatment of AIDS (PENTA) guidelines for treatment of paediatric HIV‐1 infection 2015: optimizing health in preparation for adult life

6. SARS-CoV-2 lineage dynamics in England from September to November 2021: high diversity of Delta sub-lineages and increased transmissibility of AY.4.2

7. Vessel wall magnetic resonance and arterial spin labelling imaging in the management of presumed inflammatory intracranial arterial vasculopathy

8. Antenatal Seroprevalence of Zika and Chikungunya Viruses, Kingston Metropolitan Area, Jamaica, 2017-2019

9. Cohort Profile: The Hepatitis C Virus (HCV) Research UK Clinical Database and Biobank

11. Genomic reconstruction of the SARS-CoV-2 epidemic in England

12. Serological profile of first SARS-CoV-2 reinfection cases detected within the SIREN study

14. Evidence for HIV-1 cure after CCR5 Delta 32/Delta 32 allogeneic haemopoietic stem-cell transplantation 30 months post analytical treatment interruption: a case report

16. The impact of Spike mutations on SARS-CoV-2 neutralization

19. Laboratory biomarkers associated with COVID-19 severity and management

20. Portable real-time colorimetric LAMP-device for rapid quantitative detection of nucleic acids in crude samples

22. An integrated national scale SARS-CoV-2 genomic surveillance network

24. Associations between baseline characteristics, CD4 cell count response and virological failure on first-line efavirenz

25. Nosocomial transmission of influenza: A retrospective cross-sectional study using next generation sequencing at a hospital in England (2012-2014)

26. HIV-1 remission following CCR5 Delta 32/Delta 32 haematopoietic stem-cell transplantation

27. Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance

28. Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug Resistance

29. A high HIV-1 strain variability in London, UK, revealed by full-genome analysis:Results from the ICONIC project

30. Near full-length genomic sequencing and molecular analysis of HIV-infected individuals in a network-based intervention (TRIP) in Athens, Greece: evidence that transmissions occur more frequently from those with high HIV-RNA

31. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): Extended follow-up results of a randomised, open-label, non-inferiority trial

32. What we know and what we don't know about perinatal Zika virus infection: a systematic review

34. A High HIV-1 strain variability in London, UK, revealed by full-genome analysis: Results from the ICONIC project

35. Report from the First EPIICAL (Early-treated Perinatally HIV-infected Individuals: Improving Children's Actual Life with Novel Immunotherapeutic Strategies) General Assembly meeting, 9–11 November 2017, Rome, Italy

36. Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption

37. Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial

39. The EPIICAL project: an emerging global collaboration to investigate\ud immunotherapeutic strategies in HIV-infected children

40. HIV-1 Drug Resistance and Second-Line Treatment in Children Randomized to Switch at Low Versus Higher RNA Thresholds

41. P0478 : NKG2D-dependent cross-talk between NK cells and CD4 T cells in chronic hepatitis B

45. PWE-138 Treatment Of Patients with Chronic Hepatitis C Genotype 1 and Advanced Fibrosis with Protease Inhibitors- Il28B Discordance Results in Early Viral Decline but Late Relapse: Abstract PWE-138 Table

46. 1224 TIMING AND CHARACTERISTICS OF DRUG RESISTANCE MUTATIONS (DRMS) IN CHRONIC HEPATITIS C PATIENTS DURING AND AFTER TREATMENT WITH PROTEASE INHIBITOR THERAPY AT A SINGLE CENTRE

48. Development of the R263K Mutation to Dolutegravir in an HIV-1 Subtype D Virus Harboring 3 Class-Drug Resistance.

Catalog

Books, media, physical & digital resources